Company Overview
Snapshot
Founded in January 2016 by Todd Holmes and Ilan Carmeli, Beaconcure operates with 11–50 employees. The company has raised $17.9 million across four funding rounds from three investors. In March 2023, Beaconcure secured a Series B round, led by NewVale Capital.
Business overview
Beaconcure develops an automated solution, supported by machine learning and natural language processing, for clinical data validation. Its core product, Verify, is a SaaS system designed to manage clinical trial output data and automate the validation of statistical analysis for regulatory submissions in drug and vaccine development. The company serves the pharmaceutical industry, healthcare providers, and academic institutions, operating within the Health Tech & Life Sciences sector, with a focus on digital healthcare and clinical workflow.
Strategic signal
In May 2024, Beaconcure partnered with Phastar to enhance clinical trial review processes. This collaboration signals a strategic move to integrate advanced AI-powered validation into broader clinical research workflows, aiming to accelerate drug approval timelines and improve data quality for pharmaceutical companies.
Company Intelligence Q&A
- What is Beaconcure's primary offering?
- Beaconcure's primary offering is Verify, an automated SaaS system that uses machine learning and natural language processing to manage clinical trial output data and automate the validation of statistical analysis for regulatory submissions.
- When was Beaconcure founded and by whom?
- Beaconcure was founded in January 2016 by Todd Holmes and Ilan Carmeli.
- What was a significant recent partnership for Beaconcure?
- In May 2024, Beaconcure partnered with Phastar to enhance clinical trial review processes, aiming to integrate AI-powered validation into clinical research workflows.
- What was Beaconcure's most recent funding round?
- In March 2023, Beaconcure raised a Series B funding round, led by NewVale Capital.
- What is Beaconcure's total disclosed funding?
- Beaconcure has raised a total of $17.9 million across four funding rounds. The most recent was a Series B round of $14 million in March 2023, led by NewVale Capital.